Wintermute Covid treatment for further US development
Biopharmaceutical company Wintermute Biomedical has had its novel Covid-19 therapy included in the US Biden administration’s $3 billion whole of government program with a focus on accelerated development of next generation COVID-19 treatments. Melbourne-based Wintermute, which in April revealed a new anti-microbial chemistry now on sale in Australia as a hand sanitiser and surface cleaner…
Details